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S U M M A R Y
Hepatitis C virus (HCV) is probably the most common cause of liver cirrhosis and hepatocellular
carcinoma worldwide. The correct identiﬁcation of HCV genotype has important clinical implications as
a marker of responsiveness to antiviral therapy and serves as a guideline for the duration of treatment.
The VERSANT HCV Genotype 2.0 Assay failed to detect HCV genotype 2k/1b. HCV genotype 2k/1b
detection requires NS5B sequencing.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hepatitis C virus (HCV), a single-stranded enveloped RNA virus, is
probably the most common cause of liver cirrhosis and hepatocel-
lular carcinoma worldwide and is one of the major global public
health problems. HCV is highly heterogeneous, with seven
conﬁrmed major genotypes and 67 conﬁrmed subtypes. Each
genotype displays a different geographic distribution.1 Since
different HCV genotypes react differently on available antiviral
therapies, the correct identiﬁcation of HCV genotype serves as a
marker of responsiveness and an indicator for duration of treatment.
A few cases of HCV genotype 2k/1b have been reported in
Western Europe.2–5 However, to our knowledge, no cases of HCV
genotype 2k/1b have been reported in Belgium thus far.
2. Case series
Four patients in AZ Sint-Jan Bruges, Belgium were identiﬁed
retrospectively as having HCV recombinant genotype 2k/1b
between January 2012 and December 2014. The sequencing
strategy was performed using the HCV NS5B sequencing method
(Murphy et al., 2007), which has recently replaced the VERSANT
HCV Genotype 2.0 Assay (Siemens Medical Solutions Diagnostics,
Tarrytown, NY, USA) used in our laboratory.6
2.1. Patient 1
In May 2012, a 33-year-old male chronic intravenous (IV) drug
user (heroin and ‘krokodil’) from Georgia was admitted to our* Corresponding author. Tel.: +32-50-45-26-03; fax: +32-50-45-26-19.
E-mail address: marijke.reynders@azsintjan.be (M. Reynders).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).hospital with pancytopenia, B-symptoms, haematemesis, and
hepatosplenomegaly. Laboratory results revealed a signiﬁcant bone
marrow suppression: thrombocytopenia (87  106/l), anaemia
(3.25  1012/l), leukopenia (2.4  109/l), an elevated erythrocyte
sedimentation rate (120 mm/h), and a mild elevated lactate
dehydrogenase (LDH; 711 U/l); there were no other abnormalities.
Broad serological screening for possible causal agents was negative:
hepatitis B surface antigen (HBsAg), HIV (HIV Ag/antibody (Ab)),
hepatitis A virus (HAV) immunoglobulin M (IgM), cytomegalovirus
IgM, Toxoplasma gondii IgM, Epstein–Barr virus (viral capsid antigen)
IgM, Brucella spp, Coxiella burnetti, Leishmania, and Histoplasma
antibodies. Serological HCV testing was positive. HCV RNA was
detected (viral load (VL) 4.3  106 IU/ml) and initially diagnosed as
genotype 2a/2c by the VERSANT HCV Genotype 2.0 Assay, although
NS5B sequencing revealed HCV genotype 2k/1b.
A contrast-enhanced abdominal computed tomography (CT)
scan revealed hepatosplenomegaly. CT examination of the head
and thorax showed no adenopathy, and neither did a CT of the
abdomen. Further investigation revealed disseminated tuberculo-
sis (TB) with a positive intradermal tuberculosis test and ‘foreign
body’ hepatic granulomatosis possibly due to his past IV drug use.
Tuberculostatics were started and clinical symptoms regressed.
His HCV infection remained untreated considering the more urgent
need for four-drug TB therapy (rifampicin, isoniazid, ethambutol,
and pyrazinamide) and possible drug interactions. Three months
later, during a follow-up visit, he presented with general malaise,
fatigue, anorexia, and headache. A manifest regression of his
hepatosplenomegaly and adenopathy was observed. Laboratory
workup showed a normal blood cell count and decreased
inﬂammatory parameters. The HCV infection remained untreated
and the TB four-drug regimen was continued. In December 2012,
he became homeless and was lost to follow-up.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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In September 2012, a 32-year-old Russian (Chechen) man was
admitted with a provisional diagnosis of HCV genotype 2a/2c
hepatitis (HCV antibody (HCAb)-positive). He had a pre-existing
chronic hepatitis B virus (HBV) infection (HBsAg, hepatitis B
surface antibodies (HBsAb), hepatitis B core antibody (HBcAb),
and hepatitis B envelope antibody (HBeAb) positive, but hepatitis
B envelope antigen (HBeAg) negative). The patient had a history of
recurrent sexually transmitted diseases and Helicobacter pylori-
positive gastritis. HCV RNA was detected (17.0  106 IU/ml). NS5B
sequencing conﬁrmed HCV genotype 2k/1b, originally misclassi-
ﬁed as 2a/2c. For his HCV infection, he received treatment with
peginterferon (PEG-IFN)/ribavirin (RBV) therapy, with an initial
decrease in the viraemia, but no sustained virological response
(SVR) after 24 weeks. Based on his HCV genotype 2k/1b and in
parallel with the chronic active HBV infection, a longer treatment
protocol of 48 weeks was necessary. In July 2013, his HCV RNA
levels remained undetectable, indicating successful clearance
of the virus. One year later, an increase in his HCV VL (28.0  106
IU/ml) and a stable HBV VL (26 IU/ml) was observed.
2.3. Patient 3
In March 2013, a 38-year-old Georgian woman was admitted
with respiratory bound upper-right abdominal quadrant pain of
many years duration. She mentioned a past HBV infection (HBsAb
and HBcAb positive, due to a needle accident). Clinical examination
was normal. Laboratory workup showed a mild elevation of liver
enzymes (alanine aminotransferase (ALT) 72 U/l and aspartate
aminotransferase (AST) 49 U/l) along with an active HCV infection
with HCAb positivity and detectable HCV RNA (VL 2.4  106 IU/ml).
NS5B sequencing revealed HCV genotype 2k/1b. PEG-IFN treat-
ment was started (intended duration 48 weeks). After 32 weeks of
therapy, the treatment was stopped due to progressive and
intolerable neurological complaints, including muscular weakness,
general malaise, fatigue, and a depressive mood disorder. During
follow-up visits, laboratory parameters returned to the physiolog-
ical range and the HCV viraemia remained undetectable, indicating
successful clearance of the virus.
2.4. Patient 4
In December 2014, a fourth case of HCV 2k/1b was diagnosed in a
34-year-old Chechen man. An HCV VL of 16.9  106 IU/ml was
observed, as well as a negative HBV serology. He refused antiviral
therapy and a diagnostic liver biopsy, stating that he wanted to be
treated and followed in his homeland. Once discharged from prison,
the patient was lost to follow-up without prescription treatment.
3. Discussion
The recombinant HCV genotype 2k/1b was ﬁrst described in
Saint Petersburg in 2002 in IV drug users.7 Since its discovery, only
a few cases of HCV genotype 2k/1b have been reported in Western
Europe.2–5 In all four cases, the patients originated from the
Caucasus, where HCV genotype 2k/1b is endemic. A sequencing
strategy led to the detection of HCV genotype 2k/1b. However,
clinical laboratories often use the VERSANT HCV Genotype
2.0 Assay for routine HCV genotyping. This molecular second-
generation line probe assay (LiPA) may potentially misclassify
these HCV strains as HCV genotype 2a/2c.8,9 Based on these
ﬁndings, the number of patients infected with HCV 2k/1b may be
underestimated.
It is widely recognized that patients infected with genotype
2 in particular are more likely to achieve a faster SVR thanpatients infected with genotype 1. Seventy-ﬁve to eighty
percent of genotype 2 patients achieve SVR after 24 weeks of
antiviral treatment (PEG-IFN plus RBV) versus only 50% of
genotype 1 patients after 48 weeks treatment. Furthermore, in
general 70% (genotype 1a) to 80% (genotype 1b) of patients
achieve a SVR when protease inhibitors are included in the
therapy.10
Due to the limited information on susceptibility of the
recombinant 2k/1b HCV genotype to antiviral treatment, no
recommendations exists on the duration of therapy or optimal
therapy.11 Studies show discrepant results regarding IFN
treatment of HCV 2k/1b and SVR. One study has shown a
higher susceptibility of the 2k/1b genotype to PEG-IFN/RBV
treatment than another.4,10 In 2014, Hedskog et al. showed
lower SVR rates among patients infected with recombinant HCV
forms on direct-acting antiviral (DAA) therapy.11 HCV 2k/1b
patients could therefore be considered for longer treatment
durations or DAA therapy.4,9,10 Regarding our cases, a longer
PEG-IFN-based treatment, 48 weeks instead of the expected 24-
week protocol for genotype 2a/2c, was needed for two patients
to obtain SVR. A new DAA, sofosbuvir, has recently been
approved in Europe for the treatment of chronic HCV patients
(all genotypes) and has shown high rates of SVR when given
with RBV.12 Based on the actual strict reimbursement criteria in
Belgium, none of these 2k/1b patients would have been eligible
for treatment with sofosbuvir at the moment of diagnosis and
genotyping (infections with recombinant HCV strains are not
mentioned within these criteria). The detection of these cases
stresses the importance of determining the HCV genotype by
NS5B sequencing. Exact HCV genotyping and subtyping facil-
itates treatment options and serves as a guide for clinical
decision-making.
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